Summary: In a randomised, double-blind, placebo-controlled Phase I dose-escalation study of 40 healthy Chinese volunteers, the dual GLP-1/GIP receptor agonist BGM0504 was generally safe and well tolerated. Pharmacokinetics were dose-linear across 2.5 to 15 mg and supported once-weekly dosing, and mean body-weight reduction from baseline rose with dose (-3.24%, -6.26%, -7.09% and -8.30% in the 2.5, 5, 10 and 15 mg groups). Gastrointestinal events were the most frequent adverse effects.
PICO Summary
| Element | Detail |
|---|---|
| Population | 40 healthy adult volunteers in China; randomised, double-blind, placebo-controlled, single-centre Phase I dose-escalation study. |
| Intervention | BGM0504, a dual GLP-1/GIP receptor agonist, given subcutaneously: a single 2.5 mg dose, and once-weekly titrated dosing for 2 weeks to target doses of 5, 10 and 15 mg. |
| Comparison | Matching placebo by subcutaneous injection within each dose cohort. |
| Outcome | BGM0504 was generally safe and well tolerated. Cmax and AUC were linearly proportional to dose from 2.5 to 15 mg, supporting once-weekly administration. Mean change in body weight from baseline was -3.24%, -6.26%, -7.09% and -8.30% in the 2.5, 5, 10 and 15 mg groups respectively, indicating dose correlation. The most frequent adverse events were gastrointestinal (vomiting, nausea, decreased appetite, diarrhoea, abdominal distension). No confidence intervals, p-values or ARR/NNT were reported for these descriptive early-phase endpoints. |
Expert Commentary
This is a first-in-human Phase I study, and it should be read as an early safety, tolerability and pharmacokinetic signal rather than as evidence of clinical efficacy. The verdict is that BGM0504 cleared the bar a first-in-human study is designed to clear: it was generally well tolerated, exposure rose predictably with dose, and a once-weekly schedule appears pharmacokinetically reasonable. The dose-related weight reduction is encouraging and biologically consistent with dual incretin agonism, but it was measured over a very short titration in healthy volunteers and reported descriptively, without confidence intervals or formal hypothesis testing, so it cannot be taken as proof of a treatment effect. The principal limitation is the sample of only 40 healthy participants, which leaves the study underpowered to detect uncommon harms and unable to speak to efficacy in people with type 2 diabetes or obesity, the intended populations. It also warrants caution that the work was sponsored by the manufacturer, with several authors employed by the developing company, and that the largest weight changes occurred at the highest dose alongside frequent gastrointestinal events. Can I use this with my patients? Not yet; no patient should be offered BGM0504 outside a trial, because efficacy and longer-term safety in the target diseases remain unstudied. Adequately powered, longer Phase II and III trials in people with diabetes and obesity are needed before any clinical role can be considered.
References
Fan Y, Yuan J, Dong L, Yu C, Ding H, Xie D, et al. The safety, tolerability, pharmacokinetics and pharmacodynamics of an optimized dual GLP-1/GIP receptor agonist (BGM0504) in healthy volunteers: A dose-escalation Phase I study. Diabetes Obes Metab. 2025;27(4):2110-2119. doi:10.1111/dom.16203